RICHMOND, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)RX DRUG ACCESS PARTNERSHIP, founded in 2003, is a small nonprofit in the Health Care sector that reported $804K in total revenue in fiscal year 2024.
RX PARTNERSHIP IS A PUBLIC/PRIVATE PARTNERSHIP WHICH EXISTS TO INCREASE ACCESS TO ESSENTIAL MEDICATION FOR VIRGINIA'S VULNERABLE POPULATIONS AND SERVE AS A RESOURCE TO THE ORGANIZATIONS THAT SUPPORT THESE POPULATIONS.
RX PARTNERSHIP COORDINATES FREE MEDICATION FROM PHARMACEUTICAL COMPANIES AND ARRANGES FOR DISTRIBUTION DIRECTLY TO NONPROFIT, LICENSED PHARMACIES WHICH IT CREDENTIALS AND MONITORS. RX PARTNERHIP ALSO...
RX PARTNERSHIP COORDINATES FREE MEDICATION FROM PHARMACEUTICAL COMPANIES AND ARRANGES FOR DISTRIBUTION DIRECTLY TO NONPROFIT, LICENSED PHARMACIES WHICH IT CREDENTIALS AND MONITORS. RX PARTNERHIP ALSO SUPPORTS MEDICATION DELIVERY TO CLINICS WITHOUT A LICENSED PHARMACY. DURING THE YEAR ENDED JUNE 30, 2025, RX PARTNERSHIP PROVIDED ITS 31 CLINIC PARTNERS WITH ACCESS TO FREE MEDICATION TO SUPPORT OVER 11,270 UNINSURED VIRGINIANS. BRAND AND GENERIC MEDICATIONS OBTAINED THROUGH THE RX PARTNERSHIP PROGRAM FILLED OVER 62,423 PRESCRIPTIONS WITH A VALUE OF MORE THAN 23.1 MILLION. THESE MEDICATIONS TREAT CHRONIC ILLNESSES SUCH AS ASTHMA, DIABETES, HYPERTENSION, AND DEPRESSION. FOR EVERY DOLLAR DONATED TO RX PARTNERSHIP, 28 IN PRESCRPTION VALUE WAS DELIVERED TO CLINIC PATIENTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $804,095 | $845,043 | 0.0% |
| Expenses | $800,585 | $803,294 | 0.0% |
| Net Income | $3,510 | $41,749 | -0.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| AMY YARCICH | EXECUTIVE DI | 40.00 |
Officer
|
$154,269 | $18,140 | $172,409 |
| SHAWN NELSON | CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTINE BRYANT | CHAIR ELECT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| DINESH PAI | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| LINDA HINES | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| DOURINA PETERSEN | VICE-CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| DAVID EASTEP | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MONIQUE FINNERAN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SARA HEISLER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JEN KOSTYNIUK | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KATHLEEN LEWIS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KC OGBONNA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DOURINA PETERSEN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| COREY PLEASANTS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| YOGESH VERMA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CHARLIE WEBB | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CAROLINE JURAN | EX-OFFICIO | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $804,095 | $800,585 | $1,606,168 | $3,510 |
| 2024 | $845,043 | $803,294 | $1,511,552 | $41,749 |
| 2023 | $746,153 | $694,909 | $1,342,893 | $51,244 |
| 2022 | $708,293 | $671,456 | $1,172,848 | $36,837 |
| 2021 | $727,629 | $614,832 | $1,221,862 | $112,797 |
| 2020 | $665,478 | $573,771 | $1,084,118 | $91,707 |
| 2019 | $605,677 | $557,686 | $909,172 | $47,991 |
| 2018 | $518,455 | $523,266 | $856,018 | $-4,811 |
Compare RX DRUG ACCESS PARTNERSHIP with other nonprofits in Virginia and across the country.